Helsinn's oral palonosetron approved in EU
This article was originally published in Scrip
Executive Summary
An oral capsule formulation of Helsinn's 5HT3-antagonist palonosetron has been approved by EMA for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults. It was approved in the EU in 2005 as an intravenous solution formulation as Onicit and Aloxi. In 2008, the 0.5mg oral capsule was approved in the US. Chemotherapy-induced nausea and vomiting affects the majority of cancer patients undergoing chemotherapy.
You may also be interested in...
2011 Scrip 100: A new look at cancer chemoprevention
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's Xeplion recommended for EU approval for schizophrenia
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
Pfizer's Xiapex recommended for EU approval for Dupuytren's contracture
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.